Muralitharan Kengatharan

568 total citations
9 papers, 452 citations indexed

About

Muralitharan Kengatharan is a scholar working on Ophthalmology, Physiology and Molecular Biology. According to data from OpenAlex, Muralitharan Kengatharan has authored 9 papers receiving a total of 452 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Ophthalmology, 4 papers in Physiology and 3 papers in Molecular Biology. Recurrent topics in Muralitharan Kengatharan's work include Nitric Oxide and Endothelin Effects (4 papers), Retinal Diseases and Treatments (3 papers) and Immune Response and Inflammation (2 papers). Muralitharan Kengatharan is often cited by papers focused on Nitric Oxide and Endothelin Effects (4 papers), Retinal Diseases and Treatments (3 papers) and Immune Response and Inflammation (2 papers). Muralitharan Kengatharan collaborates with scholars based in United States, United Kingdom and Japan. Muralitharan Kengatharan's co-authors include Christoph Thiemermann, Sjef J. de Kimpe, John R. Vane, John P. Cooke, Peter A. Campochiaro, Katsuji Kiuchi, Raquel Lima e Silva, Masato Matsuoka, Jenny Wu and Naw Htee Khu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, British Journal of Pharmacology and American Journal of Ophthalmology.

In The Last Decade

Muralitharan Kengatharan

9 papers receiving 445 citations

Peers

Muralitharan Kengatharan

IMMUN

MB

EPIDE

PHYSI

ID

Rita Káposzta Hungary

Ingrid A. Schrijver Netherlands

Hugo Wolf Austria

K Shimada Japan

Cynthia Fourgeux France

Samir Medjane France

Kazumi Kudo Japan

Laura Teirilä Finland

Pejman Hanifi-Moghaddam Germany

Yvon Roche France

Rita Káposzta Hungary

Muralitharan Kengatharan

211 ×1.0

IMMUN

127 ×1.0

MB

166 ×2.2

EPIDE

61 ×0.9

PHYSI

177 ×3.0

ID

Citations per year, relative to Muralitharan Kengatharan Muralitharan Kengatharan (= 1×) peers Rita Káposzta

Countries citing papers authored by Muralitharan Kengatharan

Since Specialization

Citations

This map shows the geographic impact of Muralitharan Kengatharan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Muralitharan Kengatharan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Muralitharan Kengatharan more than expected).

Fields of papers citing papers by Muralitharan Kengatharan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Muralitharan Kengatharan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Muralitharan Kengatharan. The network helps show where Muralitharan Kengatharan may publish in the future.

Co-authorship network of co-authors of Muralitharan Kengatharan

This figure shows the co-authorship network connecting the top 25 collaborators of Muralitharan Kengatharan. A scholar is included among the top collaborators of Muralitharan Kengatharan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Muralitharan Kengatharan. Muralitharan Kengatharan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Wirostko, Barbara, Hiroshi Umeno, Henry H. Hsu, & Muralitharan Kengatharan. (2011). Safety and Efficacy of a Novel Topical Rho Kinase Inhibitor ATS907 in Normotensive Cynomolgus Monkeys. 52(14). 3096–3096. 1 indexed citations

2.

Kengatharan, Muralitharan, Barbara Wirostko, Hiroshi Umeno, & Henry H. Hsu. (2011). Pharmaceutical Profile of a Novel Rho Kinase (ROCK) inhibitor ATS8535 for Reduction of IOP in Glaucoma. 52(14). 3106–3106. 3 indexed citations

3.

Campochiaro, Peter A., Syed Mahmood Shah, Gulnar Hafiz, et al.. (2010). Topical Mecamylamine for Diabetic Macular Edema. American Journal of Ophthalmology. 149(5). 839–851.e1. 22 indexed citations

4.

Kiuchi, Katsuji, Masato Matsuoka, Jenny Wu, et al.. (2008). Mecamylamine Suppresses Basal and Nicotine-Stimulated Choroidal Neovascularization. Investigative Ophthalmology & Visual Science. 49(4). 1705–1705. 42 indexed citations

5.

Kengatharan, Muralitharan, et al.. (2007). Nicotinic Receptor Antagonist Mecamylamine Reduces Laser-Induced Choroidal Neovascularization in C57bl/6j Mice. 48(13). 6016–6016. 1 indexed citations

6.

Kengatharan, Muralitharan, et al.. (2001). Characteristics of the pulse waveform during altered nitric oxide synthesis in the rabbit. British Journal of Pharmacology. 133(3). 361–370. 22 indexed citations

7.

Kengatharan, Muralitharan, Sjef J. de Kimpe, & Christoph Thiemermann. (1996). Analysis of the signal transduction in the induction of nitric oxide synthase by lipoteichoic acid in macrophages. British Journal of Pharmacology. 117(6). 1163–1170. 74 indexed citations

8.

Kengatharan, Muralitharan, et al.. (1995). Endothelin-1 Mediates the Increase in Ex Vivo Coronary Vascular Resistance Induced by Hemorrhagic Shock in the Anesthetized Rat. Journal of Cardiovascular Pharmacology. 26. S422–424. 4 indexed citations

9.

Kimpe, Sjef J. de, Muralitharan Kengatharan, Christoph Thiemermann, & John R. Vane. (1995). The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure.. Proceedings of the National Academy of Sciences. 92(22). 10359–10363. 283 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact